• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

COVID-19 大流行：从感染、免疫和病理反应角度看新型冠状病毒的发病机制——多学科视角。

COVID-19 pandemic: A multidisciplinary perspective on the pathogenesis of a novel coronavirus from infection, immunity and pathological responses.

机构信息

College of Traditional Chinese medicine, Tianjin University of Traditional Chinese Medicine, Tianjin, China.

Research Center for Infectious Diseases, Tianjin University of Traditional Chinese Medicine, Tianjin, China.

出版信息

Front Immunol. 2022 Aug 26;13:978619. doi: 10.3389/fimmu.2022.978619. eCollection 2022.

DOI:10.3389/fimmu.2022.978619
PMID:36091053
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9459044/
Abstract

Coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus2 (SARS-CoV-2), has spread to more than 200 countries and regions, having a huge impact on human health, hygiene, and economic activities. The epidemiological and clinical phenotypes of COVID-19 have increased since the onset of the epidemic era, and studies into its pathogenic mechanisms have played an essential role in clinical treatment, drug development, and prognosis prevention. This paper reviews the research progress on the pathogenesis of the novel coronavirus (SARS-CoV-2), focusing on the pathogenic characteristics, loci of action, and pathogenic mechanisms leading to immune response malfunction of SARS-CoV-2, as well as summarizing the pathological damage and pathological manifestations it causes. This will update researchers on the latest SARS-CoV-2 research and provide directions for future therapeutic drug development.

摘要

新型冠状病毒（SARS-CoV-2）引发的 2019 冠状病毒病（COVID-19）已蔓延至 200 多个国家和地区，对人类健康、卫生和经济活动产生了巨大影响。自疫情爆发以来，COVID-19 的流行病学和临床表型不断增加，对其发病机制的研究对临床治疗、药物开发和预后预防至关重要。本文回顾了新型冠状病毒（SARS-CoV-2）发病机制的研究进展，重点关注了 SARS-CoV-2 导致免疫反应功能障碍的致病特征、作用部位和发病机制，并总结了它引起的病理损伤和病理表现。这将使研究人员了解 SARS-CoV-2 的最新研究进展，并为未来治疗药物的开发提供方向。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8e52/9459044/df56b8eda9cc/fimmu-13-978619-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8e52/9459044/006d7a853bce/fimmu-13-978619-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8e52/9459044/80a767812385/fimmu-13-978619-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8e52/9459044/df56b8eda9cc/fimmu-13-978619-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8e52/9459044/006d7a853bce/fimmu-13-978619-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8e52/9459044/80a767812385/fimmu-13-978619-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8e52/9459044/df56b8eda9cc/fimmu-13-978619-g003.jpg

相似文献

1
COVID-19 pandemic: A multidisciplinary perspective on the pathogenesis of a novel coronavirus from infection, immunity and pathological responses.COVID-19 大流行：从感染、免疫和病理反应角度看新型冠状病毒的发病机制——多学科视角。
Front Immunol. 2022 Aug 26;13:978619. doi: 10.3389/fimmu.2022.978619. eCollection 2022.
2
Immune response and potential therapeutic strategies for the SARS-CoV-2 associated with the COVID-19 pandemic.与 COVID-19 大流行相关的 SARS-CoV-2 的免疫反应和潜在治疗策略。
Int J Biol Sci. 2022 Feb 14;18(5):1865-1877. doi: 10.7150/ijbs.66369. eCollection 2022.
3
Advances in Pathogenesis, Progression, Potential Targets and Targeted Therapeutic Strategies in SARS-CoV-2-Induced COVID-19.SARS-CoV-2 诱导的 COVID-19 的发病机制、进展、潜在靶点和靶向治疗策略的研究进展。
Front Immunol. 2022 Apr 5;13:834942. doi: 10.3389/fimmu.2022.834942. eCollection 2022.
4
Pathogenesis-directed therapy of 2019 novel coronavirus disease.针对 2019 新型冠状病毒病的发病机制导向治疗。
J Med Virol. 2021 Mar;93(3):1320-1342. doi: 10.1002/jmv.26610. Epub 2020 Nov 10.
5
Highly pathogenic coronaviruses and the kidney.高致病性冠状病毒与肾脏。
Biomed Pharmacother. 2022 Dec;156:113807. doi: 10.1016/j.biopha.2022.113807. Epub 2022 Oct 11.
6
The outbreak of the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2): A review of the current global status.新型严重急性呼吸系统综合症冠状病毒 2（SARS-CoV-2）的爆发：当前全球状况综述。
J Infect Public Health. 2020 Nov;13(11):1601-1610. doi: 10.1016/j.jiph.2020.07.011. Epub 2020 Aug 4.
7
An updated insight into the molecular pathogenesis, secondary complications and potential therapeutics of COVID-19 pandemic.对 COVID-19 大流行的分子发病机制、继发性并发症和潜在治疗方法的最新深入了解。
Life Sci. 2020 Sep 15;257:118105. doi: 10.1016/j.lfs.2020.118105. Epub 2020 Jul 17.
8
COVID-19: A Multidisciplinary Review.新型冠状病毒肺炎（COVID-19）：多学科综述。
Front Public Health. 2020 Jul 29;8:383. doi: 10.3389/fpubh.2020.00383. eCollection 2020.
9
COVID-19: imbalanced cell-mediated immune response drives to immunopathology.COVID-19：失衡的细胞免疫反应导致免疫病理。
Emerg Microbes Infect. 2022 Dec;11(1):2393-2404. doi: 10.1080/22221751.2022.2122579.
10
SARS-CoV-2: Pathogenic Mechanisms and Host Immune Response.SARS-CoV-2：致病机制与宿主免疫应答。
Adv Exp Med Biol. 2021;1313:99-134. doi: 10.1007/978-3-030-67452-6_6.

引用本文的文献

1
Post acute CoViD-19 syndrome (PACS) - Long CoViD.新冠后综合征（PACS）——长期新冠。
Bioinformation. 2022 Oct 31;18(10):908-911. doi: 10.6026/97320630018908. eCollection 2022.
2
The safety of COVID-19 vaccines in patients with myasthenia gravis: A scoping review.新型冠状病毒肺炎疫苗在重症肌无力患者中的安全性：范围综述。
Front Immunol. 2022 Dec 22;13:1103020. doi: 10.3389/fimmu.2022.1103020. eCollection 2022.

本文引用的文献

1
Auxora vs. placebo for the treatment of patients with severe COVID-19 pneumonia: a randomized-controlled clinical trial.奥索拉与安慰剂治疗重症 COVID-19 肺炎患者的随机对照临床试验。
Crit Care. 2022 Apr 8;26(1):101. doi: 10.1186/s13054-022-03964-8.
2
Structural Basis of the Main Proteases of Coronavirus Bound to Drug Candidate PF-07321332.冠状病毒主要蛋白酶与药物候选 PF-07321332 结合的结构基础。
J Virol. 2022 Apr 27;96(8):e0201321. doi: 10.1128/jvi.02013-21. Epub 2022 Apr 7.
3
Escape and Over-Activation of Innate Immune Responses by SARS-CoV-2: Two Faces of a Coin.
SARS-CoV-2 引发的固有免疫反应的逃逸和过度激活：一枚硬币的两面。
Viruses. 2022 Mar 4;14(3):530. doi: 10.3390/v14030530.
4
Oxidative Stress-Related Mechanisms in SARS-CoV-2 Infections.氧化应激相关机制在 SARS-CoV-2 感染中的作用。
Oxid Med Cell Longev. 2022 Mar 8;2022:5589089. doi: 10.1155/2022/5589089. eCollection 2022.
5
Chronic cerebral aspects of long COVID, post-stroke syndromes and similar states share their pathogenesis and perispinal etanercept treatment logic.长新冠、中风后综合征和类似状态的慢性脑部方面具有共同的发病机制和脊柱旁依那西普治疗逻辑。
Pharmacol Res Perspect. 2022 Apr;10(2):e00926. doi: 10.1002/prp2.926.
6
Efficacy of Niclosamide vs Placebo in SARS-CoV-2 Respiratory Viral Clearance, Viral Shedding, and Duration of Symptoms Among Patients With Mild to Moderate COVID-19: A Phase 2 Randomized Clinical Trial.尼克罗米司对安慰剂在 SARS-CoV-2 呼吸道病毒清除、病毒脱落和 COVID-19 轻症至中度患者症状持续时间方面的疗效：一项 2 期随机临床试验。
JAMA Netw Open. 2022 Feb 1;5(2):e2144942. doi: 10.1001/jamanetworkopen.2021.44942.
7
Two years into COVID-19 - Lessons in SARS-CoV-2 and a perspective from papers in FEBS Letters.COVID-19 疫情两年之际：从 SARS-CoV-2 得到的教训及 FEBS Letters 中的相关论文视角。
FEBS Lett. 2021 Dec;595(23):2847-2853. doi: 10.1002/1873-3468.14226. Epub 2021 Nov 16.
8
Pathogenic Basis of Thromboinflammation and Endothelial Injury in COVID-19: Current Findings and Therapeutic Implications.新型冠状病毒肺炎血栓炎症与血管内皮损伤的发病基础：目前的研究结果与治疗意义
Int J Mol Sci. 2021 Nov 8;22(21):12081. doi: 10.3390/ijms222112081.
9
A Multifunctional Neutralizing Antibody-Conjugated Nanoparticle Inhibits and Inactivates SARS-CoV-2.一种多功能中和抗体偶联纳米颗粒抑制和失活 SARS-CoV-2。
Adv Sci (Weinh). 2022 Jan;9(2):e2103240. doi: 10.1002/advs.202103240. Epub 2021 Nov 10.
10
The Cross-Talk between Thrombosis and Inflammatory Storm in Acute and Long-COVID-19: Therapeutic Targets and Clinical Cases.急性和长新冠病毒感染中血栓形成与炎症风暴的相互作用：治疗靶点和临床病例。
Viruses. 2021 Sep 23;13(10):1904. doi: 10.3390/v13101904.